美国食品药品监督管理局 (FDA) 已批准 Moderna 公司的 COVID-19 疫苗 Spikevax ®和 mNexspike ®的 2025-2026 年配方。 更新后的 mRNA 疫苗针对的是 SARS-CoV-2 的 LP.8.1 变体，该变体在 2025 年 5 月的 FDA 疫苗和相关生物制品咨询委员会会议上 被选为首选毒株。

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

WASHINGTON -- Moderna is applying for full government approval for its COVID-19 vaccine. The company said it is submitting trial data to the Food and Drug Administration on a rolling basis over the ...

Moderna says the Food and Drug Administration has issued full approval for its COVID-19 vaccine for use in people aged 18 and older. The company made the announcement in a press release on Monday ...

Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 and older, as well as people ages 12 to 64 with at least one medical ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

Moderna (MRNA) and other biopharma companies focused on developing vaccines are trading in the red on Monday following comments from FDA official Vinay Prasad, who oversees vaccinations, that future ...

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...

Dr. Anthony Fauci on Tuesday said that there's a chance that Moderna's COVID-19 booster shot may not have FDA and CDC approval by the White House's Sept. 20 target date, though he expects that ...